By Ben Butkus

Fluidigm this week reported a 26 percent increase in fourth-quarter revenue and a 28 percent increase in full-year 2011 revenue driven heavily by uptake of its microfluidic PCR-based products for single-cell analysis.

In addition, Fluidigm executives said that the company's platform for targeted resequencing applications has been its "fastest-ramping" product to date, and that the company expects to capture additional market share in the coming year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.